Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 17 for:    A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Primary Renal Cell Carcinoma (RCC)

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02138578
Recruitment Status : Terminated (Due to changes in scanning procedure, and infeasible biopsy and baseline imaging, the trial closed for poor accrual and inability to follow patients.)
First Posted : May 14, 2014
Results First Posted : November 7, 2017
Last Update Posted : November 7, 2017
Sponsor:
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell carcinomas.

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Radiation: SBRT Radiation: RFA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma (RCC)
Study Start Date : May 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : February 2017


Arm Intervention/treatment
Experimental: Randomized SBRT
Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
Radiation: SBRT
Other Name: Stereotactic Body Radiation Therapy

Active Comparator: Randomized RFA
Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
Radiation: RFA
Other Name: Radiofrequency Ablation

Active Comparator: Non-Randomized SBRT
Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
Radiation: SBRT
Other Name: Stereotactic Body Radiation Therapy




Primary Outcome Measures :
  1. Proportion of Patients With Local Control of Disease [ Time Frame: 12 months ]
    On imaging, local control will be defined as when the treated lesion shows no enhancement.

  2. Cumulative Incidence of Grade 2 and Greater Toxicities [ Time Frame: up to 30 days after the last study treatment ]
    The number of patients reporting grade 2 and greater toxicities (for this trial the Common Terminology Criteria for Adverse Events or CTCAE was used).


Secondary Outcome Measures :
  1. Difference in Quality of Life (QOL) Scores Between SBRT and RFA Treatment Arms [ Time Frame: Pre-study, last day of treatment; 1, 3, 6, 12, 18, 24 and 36 months post treatment ]
    QOL scores will be summarized descriptively by treatment at each time point using the Convalescence and Recovery Evaluation (CARE) and SF-12 quality of life assessments . Any differences between treatment groups will be tested in the context of a general linear model with terms for treatment, time, treatment time and possibly other patient level covariates that might explain QOL.

  2. Difference in Patient Time Away (Measured in Days) Between SBRT and RFA Treatment Arms [ Time Frame: Pre-study, last day of treatment; 1, 3, 6, 12, 18, 24 and 36 months post treatment ]
    Patient time away from work/home secondary to treatment will be captured via patient questionnaire as a number of days and will be summarized descriptively by treatment group. Any differences between treatment groups will be tested by a two-sample t-test or nonparametric Mann-Whitney test.

  3. Metastasis Free Survival Time [ Time Frame: 36 months post treatment ]
  4. Overall Survival Time [ Time Frame: 36 months post treatment ]
  5. Difference in Incidence of Treatment Related Pain Between SBRT and RFA Treatment Arms [ Time Frame: Pre-study, last day of treatment; 1, 3, 6, 12, 18, 24 and 36 months post treatment ]
    All patients will be followed to assess the development of treatment related pain, and resultant usage of analgesics (drug classification and dosage) for treatment related pain. Incidence and severity of pain will be recorded for all patients, using the Common Terminology Criteria for Adverse Events (CTCAE), as will any resultant use of analgesics, and these will be compared between the two arms and analyzed in the non-randomized SBRT cohort.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for SBRT vs. RFA Randomization:

  • Patients with renal cell carcinoma less than 4 cm in maximum diameter, who are poor surgical candidates are eligible for randomization between SBRT and RFA (Renal cell carcinoma must be pathologically proven).
  • The primary tumor must be in a location amendable to RFA within the kidney.
  • Patients must be appropriate candidates for RFA, with platelets ≥50,000/mm3 and an international normalized ratio of 1.5.
  • Patients must have an ECOG (a measurement of general well being and activities of daily living; scores range from 0 to 5 where 0 represents perfect health) score ≤ 3.
  • There is no required minimum renal function (patients will be counseled about the possible need for dialysis, if applicable, just as would be the case for radical or partial nephrectomy).
  • Patients must sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.
  • Ability to understand and the willingness to sign a written informed consent.
  • If a patient is randomized to the RFA arm, but is deemed not to be an anesthesia candidate, he/she will be placed in the non-randomized SBRT cohort.

Inclusion Criteria for non-randomized SBRT arm:

  • Patients with renal cell carcinoma less than 8 cm in maximum diameter, patients with metastatic RCC who require local palliation or are progressing through systemic disease, patients who are poor surgical candidates and have tumor location not amenable to RFA, or patients who would prefer a noninvasive means of treatment are eligible for the non-randomized SBRT cohort (Renal cell carcinoma must be pathologically proven).
  • There are no limitations based on location of the primary tumor within the kidney.
  • Patients must have an ECOG score ≤ 3.
  • There is no required minimum renal function (patients will be counseled about the possible need for dialysis, if applicable, just as would be the case for radical or partial nephrectomy).
  • Patients must sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Patients younger than 18 or pregnant women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138578


Locations
Layout table for location information
United States, Michigan
University of Michigan Hospital
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Daniel Spratt, M.D. University of Michigan Rogel Cancer Center
Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT02138578    
Other Study ID Numbers: UMCC 2013.069
HUM00076618 ( Other Identifier: University of Michigan )
First Posted: May 14, 2014    Key Record Dates
Results First Posted: November 7, 2017
Last Update Posted: November 7, 2017
Last Verified: October 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Kidney Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urologic Diseases